Recent Advances in Lipid-Based Nanovesicular Delivery Systems for Melanoma Therapy

Crit Rev Ther Drug Carrier Syst. 2021;38(4):1-38. doi: 10.1615/CritRevTherDrugCarrierSyst.2021034903.

Abstract

Melanoma is one of the most aggressive forms of cancer with limited treatment options available. Successful treatment involves a combination of surgical resection of the tumor; chemotherapy and immunotherapy. Given their complex nature, the rapid development of drug resistance and metastatic spread, nanotechnology-based therapeutics are an attractive option for effective melanoma treatment. Nano-vesicular-based delivery systems hold the promise of aiding in the diagnosis and treatment of melanoma. These formulations can improve targeted delivery, deliver insoluble drugs belonging to class II, biopharmaceutical classification system, and alter drug pharmacokinetics and exposure profiles. These nanometer-sized carriers predominantly bypass the reticuloendothelial system and, thereby, improve blood circulation time and enhance tumor cell uptake with reduced toxicity. In this review, various lipid-based nano-formulations used in the diagnosis, treatment, or both for melanoma are discussed. Utilization of these na-no-formulations with a single drug or a combination of drugs, nucleic acid-based compounds (small interfering RNA, DNA) and targeting antibodies as other possibilities for melanoma are reviewed. We also present a state-of-the-art overview of alternative therapeutic approaches for the treatment of melanoma, such as photodynamic, immune, and gene therapies.

Publication types

  • Review

MeSH terms

  • Drug Compounding
  • Drug Delivery Systems
  • Humans
  • Immunotherapy
  • Lipids
  • Melanoma* / drug therapy

Substances

  • Lipids